Latest News
-
Sunday - March 29, 2020
Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:
Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery
Data from PRONOMOS study published in The New England Journal of Medicine and presented during a virtual session of the American College of Cardiology’s 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual) / The first study to demonstrate that a Factor Xa inhibitor was superior to enoxaparin in reducing risk of major venous thromboembolism in adult patients who have undergone lower limb nonmajor orthopaedic surgery / Bleeding rates were low and not significantly different between the Rivaroxaban and enoxaparin groups / Study is part of an extensive clinical programme exploring Rivaroxaban in people ranging from high risk cancer patients to those having had minor orthopaedic surgery » more
-
Saturday - March 28, 2020
Not intended for U.S. and UK Media - Data from Phase III VICTORIA study presented at American College of Cardiology’s 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)
Vericiguat significantly reduced the risk of the composite primary endpoint of cardiovascular death or heart failure hospitalization
VICTORIA is the first positive contemporary outcomes study focused exclusively on a chronic heart failure patient population following a worsening event / Treatment effect on the composite endpoint of cardiovascular death or heart failure hospitalization was consistently demonstrated regardless of background heart failure therapy / Vericiguat was well-tolerated – overall incidence rate of adverse events was comparable to placebo / Studied in a population with higher event rates than in other contemporary heart failure studies, the overall treatment benefit was driven by the patients within the lower three quartiles of baseline NT-proBNP levels, where relative risk reduction of the primary composite endpoint was up to 27% » more
-
Saturday - March 28, 2020
Not intended for U.S. and UK Media - Data from Phase III VOYAGER PAD study published in The New England Journal of Medicine and presented during the American College of Cardiology’s 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual)
Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularization
The only clinical outcome study to demonstrate the benefits of a combined antithrombotic and anti-platelet therapy in these vulnerable patients who currently have limited treatment options / Risk of acute limb ischemia was significantly reduced by 33% in these patients compared to those receiving aspirin alone / There was no significant increase in TIMI major bleeding, the principal safety outcome of the trial » more
-
Friday - March 27, 2020
Coronavirus pandemic:
Bayer planning to hold online-only stockholders’ meeting on April 28, 2020
Stockholders able to exercise right to submit questions and cast votes in a timely manner / Online stockholders’ meeting enables proposed dividend of 2.80 euros per share for 2019 to be paid on time and in full / Baumann: “Reliability for our stockholders is very important, especially during the crisis” » more
-
Tuesday - March 24, 2020
Bayer’s due diligence procedures for M&A transactions are appropriate, special audit confirms » more
-
Monday - March 23, 2020
Bayer and Curadev sign research collaboration and license agreement to develop novel STING antagonists across indications » more
-
Friday - March 20, 2020
Not intended for U.S. and UK Media - American College of Cardiology’s 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual):
Bayer announces five late-breaking presentations which include data from VICTORIA (vericiguat) and VOYAGER PAD (Xarelto™) Phase III studies
The VICTORIA study provides insight into the efficacy of vericiguat, the first soluble guanylate cyclase (sGC) stimulator investigated in patients with chronic heart failure following a worsening event / The VOYAGER PAD study investigated the use of Xarelto 2.5 mg twice daily plus aspirin 100 mg once daily in patients with symptomatic peripheral artery disease (PAD) post peripheral revascularization / Five late-breaking abstracts have been accepted for presentation and demonstrate Bayer’s ongoing commitment to the treatment of cardiovascular disease » more
-
Wednesday - March 18, 2020
Emergency aid to fight the corona pandemic in Italy:
Bayer donates one million euros for hospitals in Lombardy
Chairman of the Board of Management, Baumann: “Our emergency aid is designed to help support hospitals and hospital staff during the crisis.” » more
-
Wednesday - March 4, 2020
Bayer to advance more sustainable agricultural solutions utilizing new innovative greenhouses in Marana, Arizona
The unique Marana Greenhouses will serve as a global product design center for corn / By bringing the breeding process indoors, more seed products can be developed faster, resulting in farmers benefitting from the latest technology / Bayer’s investment in the Marana site reflects the company’s commitment to sustainability » more
-
Tuesday - March 3, 2020
Bayer Animal Health launches global Care4Pigs grant to advance swine well-being
The global Care4Pigs initiative offers EUR 30,000 in grants in support of innovations that enhance swine well-being at farm level » more
-
Thursday - February 27, 2020
Financial News Conference
Full Year 2019 Results » more
-
Thursday - February 27, 2020
Fiscal 2019:
Bayer strategically and operationally successful
Group sales advance by 3.5 percent (Fx & portfolio adj.) to 43.545 billion euros / EBITDA before special items increases by 28.3 percent to 11.503 billion euros / Core earnings per share up by 14.3 percent to 6.40 euros / Net income rises 141.4 percent to 4.091 billion euros – gain of 1.637 billion euros on sale of Currenta stake / Free cash flow of 4.214 billion euros above expectations / Proposed dividend of 2.80 euros per share / Crop Science shows solid performance in challenging environment, substantial increase in earnings due to acquired business / Pharmaceuticals shows encouraging business development / Sales growth at Consumer Health, earnings at prior-year level despite divestments / Ongoing portfolio, structural and efficiency measures implemented successfully / Glyphosate’s positive safety profile confirmed – appeal and mediation proceedings moving forward / Outlook for 2020: increase in sales, earnings and free cash flow / Ambitious sustainability targets set » more
-
Thursday - February 27, 2020
Bayer reaches agreement with stockholder Prof. Strenger on voluntary special audit of due diligence procedures » more
-
Wednesday - February 26, 2020
Personnel changes after Annual Stockholders' Meeting on April 28, 2020:
Norbert Winkeljohann to succeed Werner Wenning as Chairman of Bayer’s Supervisory Board
Werner Wenning to retire after over 50 years with Bayer / Horst Baier proposed for election as new shareholder representative » more
-
Monday - February 17, 2020
Bayer to swiftly appeal jury decision in dicamba case » more
-
Friday - February 14, 2020
Max Müller to take over the position as Head of Public Affairs Germany and EU at Bayer » more
-
Thursday - February 13, 2020
Not intended for U.S. and UK Media
Bayer to highlight data from its expanding cancer portfolio at 2020 ASCO GU Cancers Symposium
New data to be presented on the potential impact of darolutamide on cognitive function in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / 18 presentations feature data on radium-223 dichloride, including real-world analyses and investigational combination therapies in men with advanced prostate cancer » more
-
Thursday - February 13, 2020
Bayer Driving Agricultural Innovation and Sustainability with Industry-Leading Pipeline and Investment
New herbicide molecule in early development announced; first new post-emergence mode of action for broad acre weed control in 30 years / Bayer unveils a third pathway to breakthrough short stature corn through gene editing; two prior concepts advance to Phase 3 / Three generations of herbicide-tolerance traits in soybeans advance phases, representing the industry’s most robust pipeline of weed control biotechnology for soy / Largest agricultural industry R&D investment of more than 2.3 billion euros annually » more
-
Tuesday - February 11, 2020
Bayer and Nuvisan create new research unit in Berlin
Nuvisan to establish full-fledged research center with around 400 jobs in Berlin / Transaction to contribute to further strengthening healthcare cluster in Berlin / Bayer to retain significant research activities and headquarters for the company’s Pharmaceuticals Division in Berlin » more
-
Monday - February 10, 2020
Not intended for U.S. and UK Media
Bayer announces Phase III trials with new aflibercept 8mg formulation » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Monday, April 27, 2020
Q1 2020 Quarterly Statement
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV